Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma. It has a collaboration arrangement with Bristol Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts. more
Time Frame | TSVT | Sector | S&P500 |
---|---|---|---|
1-Week Return | -7.37% | -2.27% | -0.57% |
1-Month Return | -20.82% | -3.96% | 1.21% |
3-Month Return | -30.57% | -9.7% | 7.57% |
6-Month Return | -20.05% | -3.37% | 11.45% |
1-Year Return | -0.91% | 3.71% | 28.48% |
3-Year Return | -89.65% | 3.8% | 29.52% |
5-Year Return | -76.25% | 39.78% | 90.66% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 44.30M | 248.12M | 54.52M | 91.50M | 100.39M | [{"date":"2019-12-31","value":17.85,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":21.97,"profit":true},{"date":"2022-12-31","value":36.88,"profit":true},{"date":"2023-12-31","value":40.46,"profit":true}] |
Cost of Revenue | 2.98M | 5.40M | 2.52M | 26.22M | 16.92M | [{"date":"2019-12-31","value":11.36,"profit":true},{"date":"2020-12-31","value":20.58,"profit":true},{"date":"2021-12-31","value":9.6,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":64.53,"profit":true}] |
Gross Profit | 41.32M | 242.73M | 52.01M | 65.28M | 83.47M | [{"date":"2019-12-31","value":17.02,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":21.43,"profit":true},{"date":"2022-12-31","value":26.89,"profit":true},{"date":"2023-12-31","value":34.39,"profit":true}] |
Gross Margin | 93.28% | 97.83% | 95.38% | 71.34% | 83.15% | [{"date":"2019-12-31","value":95.35,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":97.5,"profit":true},{"date":"2022-12-31","value":72.93,"profit":true},{"date":"2023-12-31","value":85,"profit":true}] |
Operating Expenses | 379.29M | 387.36M | 368.47M | 328.19M | 321.08M | [{"date":"2019-12-31","value":97.92,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":95.12,"profit":true},{"date":"2022-12-31","value":84.72,"profit":true},{"date":"2023-12-31","value":82.89,"profit":true}] |
Operating Income | (337.97M) | (144.64M) | (313.95M) | (262.91M) | (216.70M) | [{"date":"2019-12-31","value":-33797300000,"profit":false},{"date":"2020-12-31","value":-14463800000,"profit":false},{"date":"2021-12-31","value":-31394800000,"profit":false},{"date":"2022-12-31","value":-26290800000,"profit":false},{"date":"2023-12-31","value":-21670300000,"profit":false}] |
Total Non-Operating Income/Expense | 17.38M | 24.52M | 313.74M | 11.69M | 9.39M | [{"date":"2019-12-31","value":5.54,"profit":true},{"date":"2020-12-31","value":7.82,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":3.73,"profit":true},{"date":"2023-12-31","value":2.99,"profit":true}] |
Pre-Tax Income | (320.59M) | (120.11M) | (292.21M) | (254.15M) | (217.57M) | [{"date":"2019-12-31","value":-32059400000,"profit":false},{"date":"2020-12-31","value":-12011400000,"profit":false},{"date":"2021-12-31","value":-29221300000,"profit":false},{"date":"2022-12-31","value":-25415300000,"profit":false},{"date":"2023-12-31","value":-21757000000,"profit":false}] |
Income Taxes | 2.75M | 18.06M | (313.66M) | (8.99K) | (8.99K) | [{"date":"2019-12-31","value":15.21,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-1737.13,"profit":false},{"date":"2022-12-31","value":-0.05,"profit":false},{"date":"2023-12-31","value":-0.05,"profit":false}] |
Income After Taxes | (323.34M) | (138.17M) | 21.44M | (254.14M) | (217.56M) | [{"date":"2019-12-31","value":-1507.92,"profit":false},{"date":"2020-12-31","value":-644.37,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-1185.22,"profit":false},{"date":"2023-12-31","value":-1014.61,"profit":false}] |
Income From Continuous Operations | (320.59M) | (120.11M) | (292.21M) | (254.15M) | (183.89M) | [{"date":"2019-12-31","value":-32059400000,"profit":false},{"date":"2020-12-31","value":-12011400000,"profit":false},{"date":"2021-12-31","value":-29221300000,"profit":false},{"date":"2022-12-31","value":-25415300000,"profit":false},{"date":"2023-12-31","value":-18389100000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (323.34M) | (138.17M) | (292.21M) | (254.14M) | (217.57M) | [{"date":"2019-12-31","value":-32334100000,"profit":false},{"date":"2020-12-31","value":-13817000000,"profit":false},{"date":"2021-12-31","value":-29221300000,"profit":false},{"date":"2022-12-31","value":-25414401300,"profit":false},{"date":"2023-12-31","value":-21757000000,"profit":false}] |
EPS (Diluted) | - | (3.68) | (12.77) | (7.58) | (4.02) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-367.66,"profit":false},{"date":"2021-12-31","value":-1276.66,"profit":false},{"date":"2022-12-31","value":-758,"profit":false},{"date":"2023-12-31","value":-402,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
TSVT | |
---|---|
Cash Ratio | 4.36 |
Current Ratio | 4.95 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
TSVT | |
---|---|
ROA (LTM) | -19.02% |
ROE (LTM) | -51.89% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
TSVT | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.55 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.45 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
TSVT | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 4.22 |
P/B | 0.76 |
Price/FCF | NM |
EV/R | 4.98 |
EV/Ebitda | NM |
2Seventy Bio Inc (TSVT) share price today is $3.27
Yes, Indians can buy shares of 2Seventy Bio Inc (TSVT) on Vested. To buy 2Seventy Bio Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in TSVT stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of 2Seventy Bio Inc (TSVT) via the Vested app. You can start investing in 2Seventy Bio Inc (TSVT) with a minimum investment of $1.
You can invest in shares of 2Seventy Bio Inc (TSVT) via Vested in three simple steps:
The 52-week high price of 2Seventy Bio Inc (TSVT) is $6.4. The 52-week low price of 2Seventy Bio Inc (TSVT) is $2.9.
The price-to-earnings (P/E) ratio of 2Seventy Bio Inc (TSVT) is
The price-to-book (P/B) ratio of 2Seventy Bio Inc (TSVT) is 0.76
The dividend yield of 2Seventy Bio Inc (TSVT) is 0.00%
The market capitalization of 2Seventy Bio Inc (TSVT) is $192.42M
The stock symbol (or ticker) of 2Seventy Bio Inc is TSVT